Updated data from the phase III APHINITY study in HER2-positive early breast cancer, with Spanish participation, show that the combination of pertuzumab, trastuzumab and chemotherapy decreases the risk of relapse and death in patients with lymph node involvement where this risk is higher.
The results, obtained after a median follow-up of 8.4 years in 4,804 patients —344 come from 40 Spanish hospitals—, were presented during the Virtual Plenary of the European Society for Medical Oncology (ESMO) and show the continued benefit of this combination when administered as intravenous treatmentpostoperative (adjuvant) in these cancer patients. In addition, the data reflect a 28 percent reduction in the risk of relapse or death, which corresponds to a absolute profit of 4.9 percent at 8 years old.
President of the German Breast Group (GBG), CEO of GBG Forschungs GmbH, and coordinator of the APHINITY study, Sibylle Loiblstated that “the trend toward a survival benefit was influenced by the lymph node-positive cohort,” and that the additional follow-up “is very important to determine the possible long-term benefit in survival and safety of this regime.”
The data show a 28% reduction in the risk of relapse or death, which corresponds to a absolute profit of 4.9 percent at 8 years old
For Tomás Pascual, study researcher and scientific director of SOLTIthe data obtained after more than 8 years of study follow-up confirm the results observed in previous analyses: “an increase in recurrence-free survival is demonstrated in those patients with HER2-positive breast cancer who have axillary involvement at diagnosis and who have been treated with chemotherapy, pertuzumab and tratsuzumab after surgery”.
“The Additional follow-up is very important to determine the possible long-term benefit on survival and safety. of this regime”
Sibylle LoiblPresident of GBG, CEO of GBG Forschungs GmbH, and coordinator of the APHINITY study
Absolute benefit of 2.6% in the postoperative period
Although the greatest benefit was still seen in people at high risk of cancer recurrence, 88.4 percent of people who received postoperative treatment with the pertuzumab regimen remained disease-free compared to those treated with trastuzumab, chemotherapy and placebo (85.8 percent), which shows a absolute profit of 2.6 percent.
Consistent with previous analyses, this effect of the pertuzumab-containing regimen was observed regardless of hormone receptor status, occurring in a 25 percent and 18 percent reduction in the risk of relapse or death in people with hormone receptor-positive disease and those with hormone receptor-negative diseaserespectively.
88.4% of people who received postoperative treatment with the pertuzumab regimen remained disease-free
According to Álvaro Rodríguez Lescure, a member of the GEICAM Breast Cancer Research Group and the study’s steering committee, “patients with HER2+ breast cancer continue to increase their most effective treatment options and, once again, they constitute the group with the greatest progress and gains in cure in the last 17 years thanks to the development and research in targeted anti-HER2 therapies“.